Applied therapeutics inc

US StockHealth Care

APLT AI Analysis Overview

Keys for Bullish View

  • Value≥4
  • Dividend≥2

Analysis Conclusion

The stock has a low value rating. If your investment strategy is value-oriented and you have long-term positions, it's crucial to adhere to your exit plan and consider reducing holdings.

APLT Current Performance

1.78%

Applied therapeutics inc

0.85%

Avg of Sector

-0.21%

S&P500

Top 10 High Relevance to APLT

  • ENGN Engene holdings inc
    Value -Trend 5Swing Trading 2Whale Interest -Dividend 1
    See more

APLT Profile

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company's lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.

Price of APLT